{"component": "definition", "props": {"groups": [{"size": 5, "snippet": "means, with respect to a particular Licensed Product that has achieved Regulatory Approval in a Major Market (the \"Original Licensed Product\"), any Licensed Product that contains a different active ingredient from that in the Original Licensed Product and that is directed against the same Mammalian Target as the Original Licensed Product, which is developed by or on behalf of BMS or its Affiliate or sublicensee as an improvement upon or potential successor to the Original Licensed Product. For clarity, it is understood that \"Second Generation Product\" shall not include new formulations, presentations, salts, or modes of delivery of the active ingredient contained in the Original Licensed Product.", "samples": [{"hash": "kRaZbPwYhOu", "uri": "/contracts/kRaZbPwYhOu#second-generation-product", "label": "Research Collaboration and Technology Transfer Agreement (Exelixis Inc)", "score": 18.0, "published": true}, {"hash": "eATcaEe2gEZ", "uri": "/contracts/eATcaEe2gEZ#second-generation-product", "label": "Research Collaboration and Technology Transfer Agreement (Exelixis Inc)", "score": 18.0, "published": true}, {"hash": "9cBr0xLNZ9V", "uri": "/contracts/9cBr0xLNZ9V#second-generation-product", "label": "Research Collaboration and Technology Transfer Agreement (Exelixis Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "licensed-product", "type": "clause", "offset": [36, 52]}, {"key": "regulatory-approval", "type": "clause", "offset": [71, 90]}, {"key": "major-market", "type": "definition", "offset": [96, 108]}, {"key": "active-ingredient", "type": "definition", "offset": [191, 208]}, {"key": "the-original", "type": "definition", "offset": [222, 234]}, {"key": "directed-against", "type": "definition", "offset": [264, 280]}, {"key": "mammalian-target", "type": "definition", "offset": [290, 306]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [360, 378]}, {"key": "successor-to-the", "type": "clause", "offset": [451, 467]}, {"key": "for-clarity", "type": "clause", "offset": [495, 506]}, {"key": "new-formulations", "type": "clause", "offset": [576, 592]}, {"key": "delivery-of-the", "type": "clause", "offset": [628, 643]}, {"key": "contained-in", "type": "definition", "offset": [662, 674]}], "hash": "267d34abd65b1abda1b1b2d394fa26da", "id": 1}, {"size": 4, "snippet": "means any Combination Product containing or comprising the compound known as ABT-493, a Product that is an HCV NS3/4A protease inhibitor, and one or more other ingredients that are therapeutically or biologically active and are not themselves Products. For purposes of clarity, a Second Generation Product may consist of more than one combination, each containing ABT-493.", "samples": [{"hash": "2OYiDguMWl2", "uri": "/contracts/2OYiDguMWl2#second-generation-product", "label": "Collaborative Development and License Agreement (Enanta Pharmaceuticals Inc)", "score": 32.0965092402, "published": true}, {"hash": "i8Lr5Bhh64Q", "uri": "/contracts/i8Lr5Bhh64Q#second-generation-product", "label": "Collaborative Development and License Agreement (Enanta Pharmaceuticals Inc)", "score": 25.9418206708, "published": true}], "snippet_links": [{"key": "combination-product", "type": "definition", "offset": [10, 29]}, {"key": "other-ingredients", "type": "definition", "offset": [154, 171]}, {"key": "for-purposes-of", "type": "clause", "offset": [253, 268]}, {"key": "consist-of", "type": "clause", "offset": [310, 320]}], "hash": "27bd66fea7a692925444130154a258c0", "id": 2}, {"size": 3, "snippet": "means any oral typhoid vaccine which is derived from recombinant attenuated strains of Salmonella typhi possessing; []* * This portion of the Exhibit has been omitted pursuant to a Request for Confidential Treatment under Rule 406 of the Securities Act of 1933, as amended. The complete Exhibit, including the portions for which confidential treatment has been requested, has been filed separately with the Securities and Exchange Commission.", "samples": [{"hash": "jmCB56NVALK", "uri": "/contracts/jmCB56NVALK#second-generation-product", "label": "Assignment and Variation Agreement (Peptide Therapeutics Group PLC)", "score": 18.0, "published": true}, {"hash": "bpCwa5Uhu6c", "uri": "/contracts/bpCwa5Uhu6c#second-generation-product", "label": "Assignment and Variation Agreement (Peptide Therapeutics Group PLC)", "score": 18.0, "published": true}, {"hash": "7D2NrBqiPMr", "uri": "/contracts/7D2NrBqiPMr#second-generation-product", "label": "Assignment and Variation Agreement (Peptide Therapeutics Group PLC)", "score": 18.0, "published": true}], "snippet_links": [{"key": "the-exhibit", "type": "definition", "offset": [138, 149]}, {"key": "pursuant-to-a", "type": "definition", "offset": [167, 180]}, {"key": "request-for-confidential-treatment", "type": "clause", "offset": [181, 215]}, {"key": "under-rule", "type": "clause", "offset": [216, 226]}, {"key": "securities-act-of-1933", "type": "clause", "offset": [238, 260]}, {"key": "as-amended", "type": "definition", "offset": [262, 272]}, {"key": "complete-exhibit", "type": "clause", "offset": [278, 294]}, {"key": "filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [381, 441]}], "hash": "a4992a49fd0d6bacaa41651d8ba4f8e7", "id": 3}, {"size": 3, "snippet": "means a formulation comprising Hydrogel Polymer in combination with a Ciba/Chiron Compound selected pursuant to Article 3 (whether or not also including a Radiopharmaceutical), together with all applicable Delivery Systems, in each case for use within the Field. Notwithstanding the foregoing, except as provided under Section 2.2 below, Second Generation Products shall not include any such formulation incorporating [*] or Ciba/Chiron Compound that is a Platelet Antagonist.", "samples": [{"hash": "9QvpUtjcCvU", "uri": "/contracts/9QvpUtjcCvU#second-generation-product", "label": "Collaboration and License Agreement (Focal Inc)", "score": 18.0, "published": true}, {"hash": "150OBgmPImA", "uri": "/contracts/150OBgmPImA#second-generation-product", "label": "Collaboration and License Agreement (Focal Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "in-combination", "type": "definition", "offset": [48, 62]}, {"key": "article-3", "type": "clause", "offset": [112, 121]}, {"key": "delivery-systems", "type": "definition", "offset": [206, 222]}, {"key": "each-case", "type": "definition", "offset": [227, 236]}, {"key": "the-field", "type": "definition", "offset": [252, 261]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [263, 292]}, {"key": "section-22", "type": "clause", "offset": [319, 330]}], "hash": "ac100fc05e064a06275b5d0ecc469eaa", "id": 4}, {"size": 2, "snippet": "has the meaning set forth in Section 6.5.2(b).", "samples": [{"hash": "kE0B3kMsI3a", "uri": "/contracts/kE0B3kMsI3a#second-generation-product", "label": "Co Development and Option Agreement (Alector, Inc.)", "score": 30.015742642, "published": true}, {"hash": "1WnmvkCFaL9", "uri": "/contracts/1WnmvkCFaL9#second-generation-product", "label": "Co Development and Option Agreement (Alector, Inc.)", "score": 29.7775496235, "published": true}], "snippet_links": [], "hash": "d3f935c2fca352cd38a33fc171c1f4bc", "id": 5}, {"size": 2, "snippet": "means a Product containing a different Selected Scaffold from any Selected Scaffold in a Commercialized Product but which contains, as its active ingredient, a Program Antibody that is generated using the same Merck Sequence Pair as the Program Antibody that is the active ingredient in the Commercialized Product and which requires at least one new Phase III Clinical Trial to receive a Marketing Authorization.", "samples": [{"hash": "2SEqGKwRQEa", "uri": "/contracts/2SEqGKwRQEa#second-generation-product", "label": "Research and License Agreement (Zymeworks Inc.)", "score": 28.2525667351, "published": true}, {"hash": "jkX6gFo5uvs", "uri": "/contracts/jkX6gFo5uvs#second-generation-product", "label": "Research and License Agreement (Zymeworks Inc.)", "score": 28.2142368241, "published": true}], "snippet_links": [{"key": "active-ingredient", "type": "definition", "offset": [139, 156]}, {"key": "program-antibody", "type": "definition", "offset": [160, 176]}, {"key": "sequence-pair", "type": "definition", "offset": [216, 229]}, {"key": "the-program", "type": "clause", "offset": [233, 244]}, {"key": "phase-iii-clinical-trial", "type": "definition", "offset": [350, 374]}, {"key": "to-receive", "type": "definition", "offset": [375, 385]}, {"key": "marketing-authorization", "type": "clause", "offset": [388, 411]}], "hash": "e4f9cf087c478c6a82c01f859d567e88", "id": 6}, {"size": 2, "snippet": "means any erythropoietin product or service that is: (a) any derivative, modification, mutant, fragment or peptide analog of erythropoietin or (b) any other therapy involving the administration of erythropoietin such as gene or cell therapy processes or cell therapy products, carrier systems, fusion proteins, polymers and peptides. For purposes of clarity, the definition of Second Generation Product does not include any small molecule. For the purpose of clarity, the definition of Second Generation Product includes versions of GA-EPO that are long acting.", "samples": [{"hash": "g5e9Xq0hhzJ", "uri": "/contracts/g5e9Xq0hhzJ#second-generation-product", "label": "Exclusive License Agreement (Shire Pharmaceuticals Group PLC)", "score": 21.0, "published": true}, {"hash": "jIDzUO3jX5K", "uri": "/contracts/jIDzUO3jX5K#second-generation-product", "label": "Exclusive License Agreement (Transkaryotic Therapies Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "product-or-service", "type": "clause", "offset": [25, 43]}, {"key": "administration-of", "type": "clause", "offset": [179, 196]}, {"key": "cell-therapy", "type": "definition", "offset": [228, 240]}, {"key": "for-purposes-of", "type": "clause", "offset": [334, 349]}, {"key": "the-definition-of", "type": "definition", "offset": [359, 376]}, {"key": "small-molecule", "type": "definition", "offset": [424, 438]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [440, 458]}], "hash": "add10b31b9e4d1903192fe3e8829088a", "id": 7}, {"size": 2, "snippet": "means: (a) a follow-on Genentech Product that (i) in the case of a Genentech Product that is a Soluble Receptor Protein, incorporates the same therapeutically relevant sequences as are incorporated in an existing Genentech Product, or (ii) in the case of a Genentech Product that is a Target Modulator, is directed at or otherwise interacts with the same target that an existing Genentech Target Modulator Product is directed at or otherwise interacts with; provided that in each case (i) and (ii) above, such follow-on Genentech Product is developed for the same indication(s) as that existing Genentech Product; or (b) a follow-on Renovis Target Modulator Product that is directed at or otherwise interacts with the same target that an existing Renovis Target Modulator Product is directed at or otherwise interacts with, provided such follow-on Renovis Target Modulator Product is developed for the same indication(s) as that existing Renovis Target Modulator Product.", "samples": [{"hash": "il6Yxp9c8Cu", "uri": "/contracts/il6Yxp9c8Cu#second-generation-product", "label": "Collaborative Research, Development and License Agreement (Renovis Inc)", "score": 21.0, "published": true}, {"hash": "7al2AzwKkG5", "uri": "/contracts/7al2AzwKkG5#second-generation-product", "label": "Collaborative Research, Development and License Agreement (Renovis Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "genentech-product", "type": "definition", "offset": [23, 40]}, {"key": "in-the-case", "type": "clause", "offset": [50, 61]}, {"key": "provided-that", "type": "clause", "offset": [458, 471]}, {"key": "each-case", "type": "definition", "offset": [475, 484]}], "hash": "a2bcb427238bd7d57fb518ef2957d03a", "id": 8}, {"size": 2, "snippet": "means any product comprising a Second Generation Agent.", "samples": [{"hash": "b9lrdDsLHbi", "uri": "/contracts/b9lrdDsLHbi#second-generation-product", "label": "Strategic Collaboration Agreement (EPIX Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "gf2lKOt2BDv", "uri": "/contracts/gf2lKOt2BDv#second-generation-product", "label": "Strategic Collaboration Agreement (Epix Medical Inc)", "score": 18.0, "published": true}], "snippet_links": [], "hash": "d7bd92e2fd284f0b1376bdd3bf793d59", "id": 9}, {"size": 1, "snippet": "means Product manufactured using the Second Generation Process.", "samples": [{"hash": "9K8sdAbsES2", "uri": "/contracts/9K8sdAbsES2#second-generation-product", "label": "Enbrel Supply Agreement (Amgen Inc)", "score": 21.0, "published": true}], "snippet_links": [], "hash": "fa268ab10c3cf10bb4b2e9aac67b3190", "id": 10}], "next_curs": "CmYSYGoVc35sYXdpbnNpZGVyY29udHJhY3RzckILEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIic2Vjb25kLWdlbmVyYXRpb24tcHJvZHVjdCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 36, "snippet": "means, with respect to a particular Licensed Product that has achieved Regulatory Approval in a Major Market (the \"Original Licensed Product\"), any Licensed Product that contains a different active ingredient from that in the Original Licensed Product and that is directed against the same Mammalian Target as the Original Licensed Product, which is developed by or on behalf of BMS or its Affiliate or sublicensee as an improvement upon or potential successor to the Original Licensed Product. For clarity, it is understood that \"Second Generation Product\" shall not include new formulations, presentations, salts, or modes of delivery of the active ingredient contained in the Original Licensed Product.", "title": "Second Generation Product", "id": "second-generation-product", "examples": ["In the event that the <strong>Second Generation Product</strong> comprises or contains one or more Non-DAAs, then the Parties will negotiate in good faith further adjustments to the Net Sales for the <strong>Second Generation Product</strong> based on the relative value of the Non-DAA(s) to the product using the same formulas as set forth in Section 6.5.1(e)(iii) to the extent applicable.", "If Enanta elects to exercise the Co-Development and Profit Share Option with respect to any Next Generation Product (such as the <strong>Second Generation Product</strong>) [*****].", "BMEMD and the Contracting Party shall then proceed to update the Particular Conditions Section by including the changes to the corresponding <strong>Second Generation Product</strong>.", "The University represents and warrants to Medeva that the royalty arrangements described in Schedule 4(b) are, to the best of its knowledge and belief at the date of execution of this Agreement, the only royalty payments which may become due as a result of the sale of a <strong>Second Generation Product</strong>.", "The Research Program on such [*] <strong>Second Generation Product</strong> shall be initiated promptly after delivery of the [*] Ciba/Chiron Compound to Focal.", "For any other <strong>Second Generation Product</strong> and for those products elaborated by the Contracting Party which BMEMD determines that are substitutive of BMEMD Data, BME MD, on a case-by-case basis and considering each <strong>Second Generation Product</strong>\u2019s characteristics will determine if such product is subjected or not to above mentioned Agreement\u2019s Annex 4 fees regime or it is subjected to the ordinary Distribution License Fee and Variable Fees or if an Enterprise Agreement (\u201cE.A.\u201d) should be reached in this respect.", "The Research with respect to each <strong>Second Generation Product</strong> shall be initiated promptly upon selection of such <strong>Second Generation Product</strong> for inclusion in the Research Program in accordance with the Research Plan and Budget.", "Except as required by law, none of the parties hereto shall publish or publicly disclose any results, information or data arising from any Research or Product Development for a First Generation Product or <strong>Second Generation Product</strong> without the prior written consent of Focal and the Developing Party, which consent shall not be unreasonably withheld.", "Project by notice in writing without proceeding to carry out any further study or work or proceeding to commercialise a <strong>Second Generation Product</strong>.", "Each party undertakes to inform the other party of any additional third party royalties promptly after identifying that such royalties may be applicable to a Typhoid Project or to a <strong>Second Generation Product</strong> arising from such Typhoid Project."], "related": [["collaboration-product", "Collaboration Product", "Collaboration Product"], ["diagnostic-product", "Diagnostic Product", "Diagnostic Product"], ["licensed-product", "Licensed Product", "Licensed Product"], ["complex-product", "complex product", "complex product"], ["tobacco-product", "Tobacco product", "Tobacco product"]], "related_snippets": [], "updated": "2025-07-06T21:56:45+00:00"}, "json": true, "cursor": ""}}